VERAPAMIL HYDROCHLORIDE tablet, film coated, extended release

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Active ingredient:

VERAPAMIL HYDROCHLORIDE (UNII: V3888OEY5R) (VERAPAMIL - UNII:CJ0O37KU29)

Available from:

Preferred Pharmaceuticals Inc.

INN (International Name):

VERAPAMIL HYDROCHLORIDE

Composition:

VERAPAMIL HYDROCHLORIDE 120 mg

Administration route:

ORAL

Prescription type:

PRESCRIPTION DRUG

Therapeutic indications:

Verapamil hydrochloride extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacolo

Product summary:

Verapamil Hydrochloride Extended-Release Tablets, USP, 120 mg are supplied as brown colored, oval, biconvex, film-coated tablets with ‘292’ debossed on one side and plain on the other side.120 mg (brown colored) Bottles of 30 NDC 68788-6328-3 Bottles of 60 NDC 68788-6328-6

Authorization status:

Abbreviated New Drug Application

Summary of Product characteristics

VERAPAMIL HYDROCHLORIDE- VERAPAMIL HYDROCHLORIDE TABLET, FILM COATED,
EXTENDED RELEASE
PREFERRED PHARMACEUTICALS INC.
----------
VERAPAMIL HYDROCHLORIDE EXTENDED-RELEASE TABLETS, USP
RX ONLY
DESCRIPTION
Verapamil Hydrochloride Extended-Release Tablets, USP are calcium ion
influx inhibitor
(slow-channel blocker or calcium ion antagonist). Verapamil
Hydrochloride Extended-
Release Tablets, USP are available for oral administration as brown
colored, oval,
biconvex, film-coated tablets containing 120 mg verapamil
hydrochloride, USP
(equivalent to 111.08 mg verapamil free base), as brown colored, oval,
biconvex, film-
coated tablets containing 180 mg verapamil hydrochloride, USP
(equivalent to 166.62
mg verapamil free base), and as brown colored, oval, biconvex,
film-coated tablets
containing 240 mg verapamil hydrochloride, USP (equivalent to 222.16
mg verapamil
free base). The tablets are designed for sustained release of the drug
in the
gastrointestinal tract; sustained-release characteristics are not
altered when the tablet is
divided in half.
The structural formula of verapamil HCl, USP is given below:
Benzeneacetonitrile,
α-[3-[[2-(3,4-dimethoxyphenyl)-ethyl]methylamino]propyl]-3,4-
dimethoxy-α-(1-methylethyl) hydrochloride
Verapamil HCl, USP is an almost white, crystalline powder, practically
free of odor, with a
bitter taste. It is soluble in water, freely soluble in chloroform,
sparingly soluble in alcohol
and practically insoluble in ether. Verapamil HCl, USP is not
chemically related to other
cardio active drugs.
In addition to verapamil HCl, USP, the Verapamil Hydrochloride
Extended-Release
Tablets, USP contain the following inactive ingredients: colloidal
silicon dioxide,
hypromellose, magnesium stearate, microcrystalline cellulose,
polyethylene glycol,
povidone, sodium alginate, and titanium dioxide. The following are the
color additives per
tablet strength:
Strength (mg)
Color Additive(s)
C
H
N O ·HCl M.W. 491.06 g/mol
27
38
2
4
120
Ferric Oxide Yellow, Ferric Oxide Red and Ferric Oxide Black
180
Ferr